JohnFPaoliniMDPhD

Chief Medical Officer

Dr. Paolini is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

A Pilot Study of KPL-914 in Recurrent Pericarditis Start of enrollment: 2018 Jan 24
Completed
Phase 2

PubMed

39 citations
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial
Allan L. Klein, David Lin, Paul Cremer, Saifullah Nasir, Sushil Allen Luis
Heart. 2021-03-01
5 citations
Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.
Antonio Brucato, Michelle Z Lim-Watson, Allan Klein, Massimo Imazio, David Cella
Journal of the American Heart Association. 2022-10-18
7 citations
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.
Antonio Brucato, Alistair Wheeler, Sushil Allen Luis, Antonio Abbate, Paul C Cremer
Heart. 2023-01-27

Journal Articles

Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis
Allan L Klein, Paul Cremer, Martin Lewinter, Sushil A Luis, John F Paolini, The New England Journal of Medicine

Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19June 17th, 2020
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data and Initiates Pivotal Phase 3 Clinical TrialDecember 12th, 2018
New Agent Prevents Stroke in Patients with Atrial Fibrillation, Study SuggestsAugust 10th, 2011
Join now to see all